BioAge Labs Inc. (BIOA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, BIOA scores 31 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 6 of 20 (ROIC -35%; FCF yield 0%), signaling that the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 3 of 20 and Insider Conviction scores 3 of 20, indicating weak institutional and insider support in the rating model. Macro Regime Fit scores 8 of 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 11 of 20, with the Altman Z-Score at 5.66, Piotroski F-Score at 2/9, and Debt/Equity at 0.5.

For a prospective investor, the profile reads as a pre-profit company with negative operating and net margins, where the valuation case rests on future outcomes not visible in the reported financials. The balance sheet is comparatively stronger than the cash engine: the Altman Z-Score is elevated and reported cash is substantial relative to reported debt, which gives runway but does not offset operating losses. Upside drivers would need to come from revenue scaling or a change in the cash burn trajectory; the source data does not show either yet. Valuation tradeoffs are not measurable from the provided multiples, since P/E, EV/EBITDA, and EPS are unavailable. The sharp 52-week range ($4.81 - $25.95) against a current price of $5.94 illustrates high price volatility relative to the reported fundamentals.

Per the SEC financials, operating and net losses persisted across all three reported periods, with gross margin at 0%, operating margin at -60%, and net margin at -60%. Per the Roarable RQD rating, ROIC is -35%. The Altman Z-Score is 5.66 and the Piotroski F-Score is 2/9, both per the forensic balance sheet pillar. Reported cash fell from $354.3M (FY 2024) to $188.9M (FY 2025), while debt was $0.0M in FY 2025 against $2.5M in FY 2024.

• What specific products or pipeline assets generate or are expected to generate the $9.0M FY 2025 revenue, and what are the timelines?
• What is the cash runway implied by the FY 2025 burn rate relative to the $188.9M reported cash?
• Why are EPS, P/E, and EV/EBITDA unavailable, and what would the earnings trajectory look like under a normalized scenario?
• What drove the reported change in cash and debt between FY 2024 and FY 2025?
• What institutional, insider, or congressional holdings exist, given that the holders section is empty?